Sanctuary Advisors LLC Trims Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Sanctuary Advisors LLC lowered its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 73.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 27,924 shares of the company's stock after selling 77,000 shares during the period. Sanctuary Advisors LLC owned approximately 0.05% of Zevra Therapeutics worth $194,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company's stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the period. Stonepine Capital Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $4,858,000. Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics in the third quarter worth $3,644,000. Propel Bio Management LLC purchased a new position in Zevra Therapeutics in the third quarter valued at $1,248,000. Finally, Geode Capital Management LLC increased its holdings in Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock worth $7,246,000 after purchasing an additional 129,600 shares during the period. Institutional investors and hedge funds own 35.03% of the company's stock.

Analyst Upgrades and Downgrades

ZVRA has been the topic of a number of recent research reports. Roth Mkm upped their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, November 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Maxim Group raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $21.00.

Zevra Therapeutics Stock Performance

ZVRA traded down $0.18 on Monday, reaching $8.21. The company had a trading volume of 376,250 shares, compared to its average volume of 545,568. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76. The stock has a market capitalization of $438.22 million, a PE ratio of -4.17 and a beta of 1.97. The stock has a 50-day moving average price of $8.73 and a 200-day moving average price of $7.41.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the firm posted ($0.40) EPS. As a group, research analysts forecast that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.